Related Experiment Video
Updated: Jan 18, 2026
03:38
Unilateral Lung Volume Analysis Using Micro-CT for Enhanced Assessment of Pulmonary Fibrosis in Preclinical Models
Published on: June 20, 2025
849
Comparative analysis of biologics' effects on lung function parameters in severe asthma
Angelica Tiotiu1, Charles Pilette1, Diego Bagnasco2
1Department of Pneumology, University Hospital Saint-Luc, Brussels, Belgium; Pole Pneumology, ENT, and Dermatology-LUNS, Institute of Experimental and Clinical Research, UCLouvain, Brussels, Belgium.
Summary
Four biologics for severe asthma showed similar lung function improvements over 12 months. Benralizumab demonstrated a slight advantage in specific lung function tests at 6 months.
Area of Science:
- Pulmonology
- Pharmacology
- Clinical Medicine
Background:
- Severe asthma (SA) treatment options include biologics with modest benefits.
- Head-to-head comparisons of biologics for SA are limited.
- Understanding comparative effectiveness is crucial for optimizing SA management.
Purpose of the Study:
- To compare the efficacy of four biologics (benralizumab, dupilumab, mepolizumab, omalizumab) in severe asthma.
- To assess effects on lung function, including small airways, at 6 and 12 months.
- To provide comparative data for biologic selection in SA.
Main Methods:
- Observational, multicenter study of biologic-naive adult patients with SA.
- Treatment groups: benralizumab, dupilumab, mepolizumab, omalizumab.
- Lung function assessed via spirometry and gas dilution at baseline, 6 months (T6), and 12 months.
Main Results:
- All biologics improved lung function parameters at 6 and 12 months.
- No significant differences between groups, except for FEV1% and FVC% at T6, favoring benralizumab.
- Trends suggested dupilumab for small airways and benralizumab for distal airways, though not always significant.
Conclusions:
- All four biologics are comparably effective for severe asthma over 12 months.
- Benralizumab showed a statistically significant advantage in FEV1% and FVC% at 6 months.
- Biologic choice may consider specific airway involvement and patient characteristics.
Related Concept Videos
01:19Antiasthma Drugs: Leukotriene Modifiers
1.8K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.8K
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
1.6K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
1.6K
01:26Asthma-II: Pathophysiology and Classification
4.1K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
4.1K
01:17Drugs Used in Lower Respiratory Disorders: Overview
1.1K
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
1.1K
01:30Asthma-IV: Diagnostic and Management
3.1K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
3.1K
01:20Asthma: Pathogenesis and Management
1.2K
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
1.2K